Senda Biosciences
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $123M
Overview
A biotech creating programmable nanoparticle delivery systems inspired by nature's own nanoparticles.
Genetic DiseasesMetabolic Diseases
Technology Platform
A platform that decodes natural interkingdom nanoparticles to design synthetic, programmable delivery systems for a wide range of therapeutic payloads.
Funding History
1Total raised:$123M
Venture$123M
Opportunities
Its platform could become a universal delivery solution, enabling a new wave of targeted genetic medicines beyond the liver.
Risk Factors
The platform technology is complex and unproven, facing significant technical and manufacturing hurdles before clinical validation.
Competitive Landscape
Competes with established LNP companies and other novel delivery tech firms, but its nature-inspired, programmable approach is a key differentiator.